CapsoVision Reports 19% Revenue Growth but Increases Net Loss in Q3 2025

CapsoVision, Inc. reported its financial results for the third quarter of 2025, revealing a net revenue of $3.5 million, a 19% increase from $3.0 million in the same period last year. For the nine months ending September 30, 2025, the company generated $9.6 million in revenue, up 16% from $8.3 million in the prior year. The growth was primarily driven by a 20% increase in the sales of its CapsoCam Plus capsules, which are used for small bowel imaging. However, the company also reported a net loss of $7.9 million for the quarter, compared to a loss of $5.8 million in the same quarter of 2024, reflecting a 37% increase in losses year-over-year.

Operating expenses for the third quarter rose to $9.9 million, a 33% increase from $7.5 million in the previous year. This increase was largely attributed to a significant rise in research and development costs, which surged by 35% to $6.1 million, as the company continues to invest in its product pipeline, including the development of the CapsoCam Colon capsule. General and administrative expenses also saw a notable increase of 74%, reaching $2.1 million, driven by higher payroll and professional service costs associated with being a publicly traded company.

CapsoVision's total assets as of September 30, 2025, amounted to $25.7 million, up from $16.8 million at the end of 2024. The company’s cash and cash equivalents increased to $17.8 million, bolstered by net proceeds of approximately $23.4 million from its initial public offering (IPO) completed in July 2025. The IPO allowed the company to convert all outstanding convertible preferred stock into common stock, significantly altering its capital structure. As of the end of the third quarter, CapsoVision had an accumulated deficit of $148.3 million.

In terms of operational metrics, CapsoVision reported a slight decline in gross margin, which fell to 54% from 56% in the previous year, attributed to increased costs related to customs and tariffs. The company is actively pursuing geographic expansion, with international sales accounting for 22% of total revenue in the third quarter. CapsoVision is also focused on enhancing its product offerings, including the anticipated launch of the CapsoCam Colon capsule, which is currently undergoing clinical trials and is expected to receive FDA clearance in the second quarter of 2026.

Looking ahead, CapsoVision expressed concerns regarding its ability to continue as a going concern, citing the need for additional capital to fund operations and growth initiatives. The company plans to explore further financing options to support its ongoing development and commercialization efforts, particularly as it aims to expand its product line and market presence in the gastrointestinal imaging sector.